Navigation Links
Potentia Pharmaceuticals Announces Positive Safety Data and Study Expansion in Phase I Trial for Lead Drug Candidate POT-4
Date:9/29/2008

First complement inhibitor to be tested in AMD patients

LOUISVILLE, Ky., Sept. 29 /PRNewswire/ -- Potentia Pharmaceuticals, a privately held biotechnology company developing medicines for the treatment of age-related macular degeneration (AMD) announced today that the Company's leading drug candidate, POT-4, has shown early positive safety results in its Phase I study. POT-4 is a complement inhibitor, which shuts down the complement activation cascade that could otherwise lead to local inflammation, tissue damage and upregulation of angiogenic factors such as vascular endothelial growth factor (VEGF). Based on this mechanism of action, POT-4 holds the potential to be effective against both dry and wet AMD.

"POT-4 has generated encouraging safety and tolerability data in this Phase I study and holds significant promise as a novel agent for treating AMD; a debilitating condition for which there is no cure," said Cedric Francois, President and CEO of Potentia. "As a result of the favorable early data, it was decided to expand the trial to permit further dose escalation, with the goal of prolonging the pharmacological benefit from POT-4. Potentia looks forward to the presentation of the Phase I data at a future medical conference and, with additional information gained from the extension of the study, to the initiation of Phase II trials in the future."

About AMD

AMD is the leading cause of blindness in the elderly of the western world and affects more than 10 million patients in the United States alone. The current standard of care for AMD relies primarily on angiogenesis inhibitors, an approach geared towards the approximately 10-15% of AMD patients with complications resulting from ocular angiogenesis (growth of new blood vessels and bleeding in the back of the eye). No drug currently on the market has been approved for the treatment of the remaining patients, who suffer from the so-called "dry" form of the disease.

Abo
'/>"/>

SOURCE Potentia Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
2. Cleveland Clinic Researchers Identify Mechanism Behind Platelet Function and Potentially Fatal Blood Clot Formation
3. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
4. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
5. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
6. Intellect Neurosciences, Inc. and CHDI, Inc. Enter Into Compound Testing Agreement to Evaluate OXIGON(TM) as a Potential Treatment for Huntington Disease
7. Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs
8. Potential Breakthrough Cancer Treatment Emerges from MIPS-Funded Clinical Trial Teaming CSA Medical Inc. and University of Maryland Researchers
9. Synvista Therapeutics Alagebrium Shows Potential for use in Treating Diabetes-Related Gastrointestinal Complications
10. Potential Early Warning System for Lung Cancer Identified
11. Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti-Cancer Compounds Early in Clinical Development

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)..., Sweden, December 2 DermaGen AB -...d wound healing company "Pergamum" -,today announc... from a,clinical Phase I/IIa study. DermaGen AB is...eatment for atopic dermatitis. Atopic dermatitis i...in and the skin,s weakened barrier,function make p...
(Date:12/2/2009).... 2 Novavax, Inc. (Nasda...s from the first stage of a two-stage pivotal Phas...y of the company,s 2009 H1N1 virus-like particle (...cting this study in collaboration with Avimex Labo...vaccine in Mexico and potentially other countries....
(Date:12/2/2009)... Keryx Biopharmaceutical...U.S. Food and Drug Administration (FDA) has grante..., the Company,s novel, potentially first-in-class,...nositide 3-kinase (PI3K)/Akt pathway, for the trea..., The Fast Track program of the FDA is designed...
Breaking Medicine Technology:Dermagen Reports Successful Phase I/IIa Clinical Trial for Atopic Dermatitis 2Dermagen Reports Successful Phase I/IIa Clinical Trial for Atopic Dermatitis 3Dermagen Reports Successful Phase I/IIa Clinical Trial for Atopic Dermatitis 4NOVAVAX Reports Positive Clinical Results from Pivotal Study of H1N1 Influenza Vaccine in Mexico 2NOVAVAX Reports Positive Clinical Results from Pivotal Study of H1N1 Influenza Vaccine in Mexico 3NOVAVAX Reports Positive Clinical Results from Pivotal Study of H1N1 Influenza Vaccine in Mexico 4Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Relapsed/Refractory Multiple Myeloma 2Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Relapsed/Refractory Multiple Myeloma 3Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Relapsed/Refractory Multiple Myeloma 4Phylicia Rashad Reaches Weight Loss Goal 3B Loses 35 lbs 54698 1Phylicia Rashad Reaches Weight Loss Goal 3B Loses 35 lbs 54698 2U S District Court Rules Against Lilly Regarding Gemzar Patent 54695 1U S District Court Rules Against Lilly Regarding Gemzar Patent 54695 2U S District Court Rules Against Lilly Regarding Gemzar Patent 54695 3U S District Court Rules Against Lilly Regarding Gemzar Patent 54695 4Attendance on Demand Inc Hosts Free Webinar Top 5 Tools to Control Labor Costs for Long Term Healthcare Professionals 2 3A30pm EDT August 26 2009 54692 1Attendance on Demand Inc Hosts Free Webinar Top 5 Tools to Control Labor Costs for Long Term Healthcare Professionals 2 3A30pm EDT August 26 2009 54692 2
...(BUSINESS WIRE)--Apr 4, 2007 - CytoGenix, Inc. (CY...mpleted an important,pilot study with a novel synD...nd intended to protect against the avian (H5N1),in...bust protective,effect in mice treated with the Co...ed control animals died after both groups,were cha...
...TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Apr 3, 2007 ... following a,planned meeting of the independent Da...SSERT trial of senicapoc (formerly,ICA-17043) for ...e,DMC recommended that the trial be terminated bec...on in crisis rate, the primary,endpoint. In making...
Other Medicine Technology:CytoGenix Announces Successful Testing of synDNA Vaccine for Avian,Influenza Virus 2Icagen Terminates Phase III ASSERT Study 2Icagen Terminates Phase III ASSERT Study 3
(Date:12/2/2009)...ment seen for advanced cases, study finds , ... past two decades, survival rates for advanced lun...ed modestly, a new study has found. , Researche...gnosed with stage 4 non-small cell lung cancer (NS...n was in the U.S. National Cancer Institute,s Surv...
(Date:12/2/2009)...sing incidence of obesity could counter recent inc...2 (HealthDay News) -- The overall health of the U....ades, largely because people have quit smoking in ... soon be wiped out if the rising obesity rates amo...ent trends in both smoking and obesity continue un...
(Date:12/2/2009)...ally likely to have metabolic syndrome, study find... -- Exercise alone isn,t enough to keep overweight...k for a medical condition that can lead to heart d...died linemen at Division I colleges and found that...etabolic syndrome, a group of conditions that rais...
(Date:12/2/2009)...es now available, many more to come, NIH director ...News) -- Thirteen stem cell lines have been added...funded research, and many more such lines will soo...ed Wednesday. , These are the first additional ...nded by the U.S. National Institutes of Health (NI...
(Date:12/2/2009)...IRGINIA BEACH, Va., Dec. 2 By now,...smokeless cigarettes continue to grow in popularit...ailable at the PremiumEcigarette - the new single ...te - at the amazingly low price of $14.99. ,, "...ry the e-cigarette at a very low price, before mak...
Breaking Medicine News(10 mins):Health News:Gains Made in Lung Cancer Survival 2Health News:Health Gains From Lowered Smoking Rates in Jeopardy 2Health News:Health Gains From Lowered Smoking Rates in Jeopardy 3Health News:Oversized College Football Players May Face Heart Risks 2Health News:U.S. Approves New Stem Cell Lines for Publicly Funded Research 2Health News:U.S. Approves New Stem Cell Lines for Publicly Funded Research 3Health News:A Smokeless Holiday Season? Premium Electronic Cigarette Announces New Disposable Smokeless Cigarette Product 2
...ana, and the Netherlands boost,disability field,s ...eting,with assessment results, WASHINGTON, July 1...rvices is how to allocate limited resources and fu...ent tool, developed by the American Association on...
...pproximately 200,000,women across the U.S. undergo...r ovaries are removed during a hysterectomy. While...they prepared for what comes next?, Listen to thi...graphics and,photos for free and unrestricted use ...
...immune, Inc., a privately,held biotechnology compa...,of $8.9 million of its Series D preferred stock o...erprise Associates, MPM Capital, Hunt Ventures,L.P...advance clinical development of Peptimmune,s PI-23...
...008 Anxiety is a normal human response to stress,...rder of excessive and irrational fears, such as ob...sttraumatic stress disorder. Effective treatments... result in even better results," David Tolin, Ph.D...
...evier, a leading publisher of scientific, technica...an Urology , the official journal of the European...d impact factor of 5.634. , European Urology ...idly evolving world of medicine, technology and su...
... cross contaminations including Norovirus ...a., July 16 Seal Shield LLC has begun,shipping a ...ional,keyboards with SILVER SEAL Antimicrobial pro...SEAL(TM) International Keyboard,is the world,s fir...
Other Medicine News:Health News:The Supports Intensity Scale Assessment Can be Used to Build Robust Funding Methods for Developmental Disability Services, New Research Reveals 2Health News:Peptimmune Announces the Second Close of Series D Private Financing 2Health News:D-cycloserine may improve behavioral therapy treatment for anxiety 2Health News:Seal Shield to Launch World's First Dishwasher Safe, Antimicrobial Keyboard with Multi-Language Support for International Markets 2
Acri.Sil-oI 1000
Opti-Clean II
Optimum Extra Strength Cleaner
Foreign Body Needle
Medicine Products: